You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 65 No. 9, September 2008 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  Original Contribution
 •Online Features
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (6)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Neurology
 •Neuromuscular diseases
 •Cardiovascular System
 •Radiologic Imaging
 •Cardiovascular Disease/ Myocardial Infarction
 •Congestive Heart Failure/ Cardiomyopathy
 •Cardiac Diagnostic Tests
 •Genetic Disorders
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Cardiac Involvement in Patients With Limb-Girdle Muscular Dystrophy Type 2 and Becker Muscular Dystrophy

Marie-Louise Sveen, MD; Jens Jakob Thune, MD; Lars Køber, MD, DMSci; John Vissing, MD, DMSci

Arch Neurol. 2008;65(9):1196-1201.

Objective  To investigate the extent of cardiac involvement in patients with 1 of the 12 groups of recessively inherited limb-girdle muscular dystrophy type 2 (LGMD2A-L) and Becker muscular dystrophy (BMD).

Design  Prospective screening.

Setting  Neuromuscular Clinic and Department of Cardiology at Rigshospitalet.

Patients  One hundred one patients with LGMD2A-I and BMD and 29 patients with LGMD2 and no molecular diagnosis.

Main Outcome Measures  Clinical investigation, echocardiography, and electrocardiographic findings.

Results  Cardiac involvement was present in 24 of 100 patients (24%) with LGMD2A-I and in 14 of 30 patients (47%) with BMD. Only a few patients with LGMD2A and unclassified LGMD2 had mild cardiac involvement, whereas 29% and 67% of patients with LGMD2I and LGMD2E, respectively, had cardiac involvement. Cardiac involvement was not correlated with age, muscle strength, or the level of dystrophic changes on muscle biopsy.

Conclusions  This study demonstrates a high prevalence of cardiac involvement in patients with LGMD2I, LGMD2E, and BMD. Patients with LGMD2A, LGMD2D, and unclassified LGMD2 have a much lower and milder prevalence of cardiac involvement.


Author Affiliations: Neuromuscular Research Unit, Department of Neurology, Copenhagen Muscle Research Center (Drs Sveen and Vissing), and Department of Cardiology, University of Copenhagen, Rigshospitalet (Drs Thune and Køber), Copenhagen, Denmark.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLE

This Month in Archives of Neurology
Arch Neurol. 2008;65(9):1152-1153.
FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Combined deficiency of alpha and epsilon sarcoglycan disrupts the cardiac dystrophin complex
Lancioni et al.
Hum Mol Genet 2011;20:4644-4654.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2008 American Medical Association. All Rights Reserved.